MI HYUN BAE

Dr. MI HYUN BAE

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2023 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
MBMI HYUN BAE
MI HYUN BAE
MKMi-Na Kim
Mi-Na Kim
TKTaek Soo Kim
Taek Soo Kim
SKSunjoo Kim
Sunjoo Kim
DYDongeun Yong
Dongeun Yong
MKMi-Na Kim
Mi-Na Kim
Bae MH, et al. J Korean Med Sci. 2023 Mar;38(10):e73. https://doi.org/10.3346/jkms.2023.38.e73

13 August 2018 in Journal of Clinical Laboratory Analysis
Verified
Journal Article
Closed access
PDF file
JLJae‐Hyung Lim
Jae‐Hyung Lim
CKChang‐Ki Kim
Chang‐Ki Kim
MBMI HYUN BAE
MI HYUN BAE

1 January 2015 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
BKBohyun Kim
Bohyun Kim
YCYoung-Uk Cho
Young-Uk Cho
MBMI HYUN BAE
MI HYUN BAE
SJSeongsoo Jang
Seongsoo Jang
ESEul-Ju Seo
Eul-Ju Seo
CPChan-Jeoung Park
Chan-Jeoung Park
Kim BH, et al. J Korean Med Sci. 2015 Jul;30(7):882-888. https://doi.org/10.3346/jkms.2015.30.7.882

14 October 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MBMI HYUN BAE
MI HYUN BAE
CPChan-Jeoung Park
Chan-Jeoung Park
CSCheolwon Suh
Cheolwon Suh
Myeloid-derived suppressor cells (MDSCs) are heterogeneous populations of immature myeloid cells with immunosuppressive effects that have prognostic potential in patients with malignancies; however, survival analysis studies are sparse. In this study, the prognostic implication of MDSCs was investigated in peripheral blood (PB) and bone marrow (BM) samples from 81 patients with plasma cell myeloma at diagnosis. MDSCs were quantified as monocytic MDSCs (mMDSCs) (CD11b+HLA-DR−/lowCD14+) and granulocytic MDSCs with neutrophils (gMDSCs-N) (CD11b+HLA-DR−/lowCD14−CD33+CD15+). Serum creatinine and lactate dehydrogenase levels showed a moderate correlation with all MDSC types, except BM-gMDSCs-N; mMDSCs correlated with serum β2-microglobulin level, and PB-mMDSCs showed an inverse correlation with hemoglobin. PB-mMDSC levels were significantly higher in patients with progressive disease than those in patients at diagnosis and complete response. BM-mMDSC levels in patients with progressive disease were also higher than those in patients at diagnosis. Patients with high mMDSCs showed significantly poorer prognosis than patients with low mMDSCs. Multivariate analysis showed high PB-mMDSCs (≥0.3%) as a significant adverse prognostic marker for overall survival. This study demonstrated the independent adverse prognostic impact of PB-mMDSCs in patients with myeloma. PB-mMDSC measurement using whole blood is readily accessible in clinical laboratories, and may be used as a prognostic marker in clinical practice.

18 September 2020 in Antibiotics
Verified
Journal Article
Open access
PDF file
KKKi Tae Kwon
Ki Tae Kwon
BKBongyoung Kim
Bongyoung Kim
SRSeong-Yeol Ryu
Seong-Yeol Ryu
SWSeong-Heon Wie
Seong-Heon Wie
JKJieun Kim
Jieun Kim
HPHyunjoo Pai
Hyunjoo Pai
This study examined changes in the clinical characteristics of community-acquired acute pyelonephritis (CA-APN) in South Korea between the period 2010–2011 and 2017–2018. We recruited all CA-APN patients aged ≥19 years who visited eight hospitals in South Korea from September 2017 to August 2018, prospectively. Data collected were compared with those from the previous study in 2010–2012, with the same design and participation from 11 hospitals. A total of 617 patients were enrolled and compared to 818 patients’ data collected in 2010–2011. Escherichia coli was the most common causative pathogen of CA-APN in both periods (87.3% vs. 86.5%, p = 0.680). E. coli isolates showed significantly higher antimicrobial resistance against fluoroquinolone (32.0% vs. 21.6%, p < 0.001), cefotaxime (33.6% vs. 8.3%, p < 0.001), and trimethoprim/sulfamethoxazole (37.5% vs. 29.2%, p = 0.013) in 2017–2018 than in 2010–2011. Total duration of antibiotic treatment increased from 16.55 ± 9.68 days in 2010–2011 to 19.12 ± 9.90 days in 2017–2018 (p < 0.001); the duration of carbapenem usage increased from 0.59 ± 2.87 days in 2010–2011 to 1.79 ± 4.89 days in 2010–2011 (p < 0.001). The median hospitalization was higher for patients in 2017–2018 than in 2010–2011 (9 vs. 7 days, p < 0.001). In conclusion, antimicrobial resistance of E. coli to almost all antibiotic classes, especially third generation cephalosporin, increased significantly in CA-APN in South Korea. Consequently, total duration of antibiotic treatment, including carbapenem usage, increased.

1 September 2021 in Annals of Laboratory Medicine
Verified
Journal Article
Open access
PDF file
AAAri Ahn
Ari Ahn
CPChan-Jeoung Park
Chan-Jeoung Park
MKMi-Na Kim
Mi-Na Kim
YCYoung-Uk Cho
Young-Uk Cho
SJSeongsoo Jang
Seongsoo Jang
HIHo Joon Im
Ho Joon Im
Ari Ahn, M.D., Chan-Jeoung Park, M.D., Ph.D., Min-sun Kim, M.D., Young-Uk Cho, M.D., Ph.D., Seongsoo Jang, M.D., Ph.D., Mi Hyun Bae, M.D., Ph.D., Jung-Hee Lee, M.D., Ph.D., Je-Hwan Lee, M.D., Ph.D., Kyung-Nam Koh, M.D., Ph.D., and Ho Joon Im, M.D., Ph.D.. Ann Lab Med 2021;41:479-84. https://doi.org/10.3343/alm.2021.41.5.479